ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
Previous Symbol
CUSIPN/A
Phone858-558-2871
Debt
Debt-to-Equity RatioN/A
Current Ratio6.08
Quick Ratio5.98
Price-To-Earnings
Trailing P/E Ratio-7.79
Forward P/E Ratio-9.19
P/E GrowthN/A
Sales & Book Value
Annual Sales$124.90 million
Price / Sales18.41
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.70 per share
Price / Book6.81
Profitability
EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-119.62%
Return on Equity-88.18%
Return on Assets-75.50%
Miscellaneous
Employees425
Outstanding Shares125,070,000
Market Cap$2.21 billion
OptionableOptionable
ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.08. The biopharmaceutical company earned $58.31 million during the quarter, compared to analyst estimates of $56.31 million. ACADIA Pharmaceuticals had a negative net margin of 119.62% and a negative return on equity of 88.18%. ACADIA Pharmaceuticals's quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.53) EPS. View ACADIA Pharmaceuticals' Earnings History.
When is ACADIA Pharmaceuticals' next earnings date?
What price target have analysts set for ACAD?
10 Wall Street analysts have issued 12 month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $17.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $31.70 in the next year. This suggests a possible upside of 72.5% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.
What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.
What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $30 price target on ACADIA. We recently hosted investors for a meeting with ACAD management on our Post ASH-Thrash Bus Tour. One focus of investor interest was the progress made by ACADIA on the NUPLAZID franchise since the removal of the safety concern overhang precipitated by what we view as an unfounded negative media article regarding the drug in PDP. Recall that in September 2018, the FDA announced that the label for NUPLAZID adequately characterized the known risks and that the agency still viewed benefits as outweighing risks for patients with PDP, especially in light of alternative off-label antipsych drugs." (12/5/2018)
- 2. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $69/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%)." (11/1/2018)
- 3. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (10/8/2018)
Has ACADIA Pharmaceuticals been receiving favorable news coverage?
News coverage about ACAD stock has trended somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ACADIA Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals saw a decline in short interest in the month of November. As of November 30th, there was short interest totalling 14,021,024 shares, a decline of 12.7% from the November 15th total of 16,062,827 shares. Based on an average daily trading volume, of 2,826,413 shares, the short-interest ratio is currently 5.0 days. Approximately 11.3% of the shares of the stock are sold short. View ACADIA Pharmaceuticals' Current Options Chain.
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX) and SAGE Therapeutics (SAGE).
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen R. Davis, CEO & Director (Age 57)
- Dr. Srdjan R. Stankovic, Pres (Age 61)
- Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 56)
- Ms. Elena Ridloff C.F.A., CFA, Interim CFO & Sr. VP of Investor Relations
- Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 39)
Who are ACADIA Pharmaceuticals' major shareholders?
ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (22.74%), FMR LLC (15.00%), BlackRock Inc. (7.83%), Vanguard Group Inc. (7.06%), Vanguard Group Inc (7.06%) and First Trust Advisors LP (4.70%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Which institutional investors are selling ACADIA Pharmaceuticals stock?
ACAD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Canada Pension Plan Investment Board, Janus Henderson Group PLC, Deutsche Bank AG, Wells Fargo & Company MN, Creative Planning, Renaissance Technologies LLC and Credit Suisse AG. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Which institutional investors are buying ACADIA Pharmaceuticals stock?
ACAD stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Baker BROS. Advisors LP, Peregrine Capital Management LLC, Fuller & Thaler Asset Management Inc., Fosun International Ltd, Opaleye Management Inc., Vanguard Group Inc and Vanguard Group Inc.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy shares of ACADIA Pharmaceuticals?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACAD stock can currently be purchased for approximately $18.38.
How big of a company is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a market capitalization of $2.21 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.
What is ACADIA Pharmaceuticals' official website?
How can I contact ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
